Jane Street’s Trillium Therapeutics TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-173,761
| Closed | -$3.05M | – | 11230 |
|
|
2021
Q3 | $3.05M | Buy |
173,761
+162,463
| +1,438% | +$1.9M | ﹤0.01% | 3619 |
|
|
2021
Q2 | $109K | Sell |
11,298
-24,245
| -68% | -$228K | ﹤0.01% | 9221 |
|
|
2021
Q1 | $381K | Buy |
35,543
+21,724
| +157% | +$269K | ﹤0.01% | 7306 |
|
|
2020
Q4 | $204K | Sell |
13,819
-58,368
| -81% | -$842K | ﹤0.01% | 6930 |
|
|
2020
Q3 | $1.02M | Buy |
+72,187
| New | +$720K | ﹤0.01% | 4062 |
|
|
2020
Q2 | – | Sell |
-31,505
| Closed | -$195K | – | 7750 |
|
|
2020
Q1 | $124K | Buy |
31,505
+2,917
| +10% | +$11K | ﹤0.01% | 4862 |
|
|
2019
Q4 | $29K | Buy |
+28,588
| New | +$10.9K | ﹤0.01% | 4941 |
|
|
2019
Q2 | – | Sell |
-22,494
| Closed | -$14K | – | 6003 |
|
|
2019
Q1 | $14K | Sell |
22,494
-2,168
| -9% | -$2.65K | ﹤0.01% | 4913 |
|
|
2018
Q4 | $43K | Buy |
+24,662
| New | +$74K | ﹤0.01% | 4737 |
|
|
2017
Q1 | – | Sell |
-19,230
| Closed | -$109K | – | 4869 |
|
|
2016
Q4 | $109K | Buy |
+19,230
| New | +$191K | ﹤0.01% | 3858 |
|
Other funds holding TRIL
Jane Street's TRIL Position: Q4 2021 in Review
Jane Street sold out of Trillium Therapeutics (TRIL) in Q4 2021, closing a stake of 173,761 shares — an estimated $3.05M sold.
Jane Street first reported a position in TRIL in Q4 2016 and held it in 10 quarters. The position peaked at $3.05M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Jane Street reported no remaining Trillium Therapeutics position as of Q4 2021 after selling out during the quarter.
- Jane Street sold 173,761 Trillium Therapeutics shares in Q4 2021, an estimated $3.05M.
- Jane Street first reported a position in Trillium Therapeutics in Q4 2016 and held it in 10 quarters.
- Jane Street's Trillium Therapeutics position peaked at $3.05M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics as of Q4 2021.
Based on Jane Street's 13F filing for Q4 2021, filed 15 Feb 2022.